HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $44
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Oren Livnat maintains a Buy rating on Tarsus Pharmaceuticals (NASDAQ:TARS) and raises the price target from $40 to $44.
June 26, 2023 | 10:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Tarsus Pharmaceuticals and raises the price target from $40 to $44.
The raised price target by HC Wainwright & Co. indicates a positive outlook for Tarsus Pharmaceuticals. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100